Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Background: \- Radiation is a common treatment for prostate cancer. It helps damage tumor cells and causes them to die. Radiation can be effective, but some tumors may be harder to treat with radiation or even with surgery. This happens to a small number of men who have either radiation or surgery for prostate cancer. Most men who have these hard-to-treat tumors do not know if the tumor has recurred only in the prostate or has spread to another area. Also, men whose prostate cancer has recurred only after radiation may have different treatment options. This study will use improved imaging studies to better understand why some men do not respond as well to initial radiation treatments. Objectives: \- To use detailed imaging studies to look at the results of local radiation therapy for prostate cancer. Eligibility: * Men at least 18 years of age who are scheduled to have radiation for prostate cancer. * Men at least 18 years of age whose prostate cancer has returned after earlier treatments. Design: * All participants will have a medical history and physical exam. Blood and urine samples will be collected. Imaging studies will be used to evaluate the cancer at the start of the study. * All participants will have an initial full magnetic resonance imaging (MRI) scan of the prostate. Tumor and healthy tissue samples will be collected. * Those whose cancer has recurred after treatment will discuss possible treatment options with the study doctors. * Participants who are scheduled to have radiation will have radiation therapy. This will be given according to the current standard of treatment. * After radiation, participants will have regular follow-up tests and imaging studies. They will have another full MRI scan 6 months after the end of radiation treatment.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Mężczyźni w wieku ponad 18 lat z nielechonym rakiem prostaty
- •Potwierdzony histologicznie lub cytologicznie rak prostaty
- •Rak prostaty średniego lub wysokiego ryzyka
- •Brak wcześniejszych zabiegów na prostacie (operacja, radioterapia, kriochirurgia) lub wcześniejszego leczenia hormonalnego
- •Radioterapia planowana jako główne leczenie raka prostaty
- •Mężczyźni w wieku ponad 18 lat, u których rak prostaty nawrócił po poprzednim leczeniu
- •Historia potwierdzenia histologicznego lub cytologicznego raka prostaty
- •Dostępna dokumentacja poprzedniej radioterapii jako głównego leczenia
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 120 Years
- Last updated (source)
- July 17, 2026
- Sex
- Male only
Locations (1)
National Institutes of Health Clinical Center
Bethesda, United States
Trial contact
Rukayat O Salau
Deborah E Citrin, M.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/15/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.